Is there another way to think about Alpha Synuclein?
Alberto Espay and Anthony Lang think through Parkinson’s Disease and Alpha Synuclein and come up with some compelling hypotheses
Is there a better way to do Parkinson’s Research?
With a 0 for 18 track record in phase 3 clinical trials for a disease modifying treatment, is it time to wonder if there are other ways to tackling Parkinson’s that would be effective? Alberto Espay and Anthony Lang have a view.